Finding cures for children's genetic diseases


CMRI attends HUPO 2017

CMRI Director, Professor Roger Reddel and Professor Phil Robinson, both co-leaders of ProCan, met with proteomics experts at the annual Human Proteome Organization (HUPO) meeting in San Diego, to discuss the Cancer Moonshot consortium, which aims to accelerate cancer research and ensure the best cancer treatments reach patients faster.

Children’s Medical Research Institute (CMRI) launched the ProCan facility last year, which was the first to be included in an agreement with the United States Government’s National Cancer Institute, linking ProCan to the Cancer Moonshot initiative. Now proteome leaders from 10 countries and 18 institutions, all with unique expertise, have come together to help with the Cancer Moonshot. And much of the discussion centred around ProCan.

“The response to ProCan has always been this is too big to fail. There is nothing like it, it’s unique,” Professor Phil Robinson said.

“It was the first time the members of the consortium met to discuss what we would do with this consortium, and how we may benefit and truly add combined efforts to the overall project.”

Professor Robinson and Professor Reddel successfully established new collaborations with proteomics experts present, with one researcher from the University of British Columbia in Vancouver offering to contribute his data, which could essentially save ProCan researchers over two years of research.

“That’s the kind of can-do thing that happened [at this meeting],” Professor Robinson added. “It brought a lot of proteomics technology together with a common purpose. Each of the proteome experts has a different approach to the way they look at different cancers. If we give them the Swath data, which is what ProCan collects, it will add value to what they’re doing in a huge way.”